Navigation Links
Piedmont Pharmaceuticals Secures $8.5 Million Investment
Date:11/12/2007

GREENSBORO, N.C., Nov. 12 /PRNewswire/ -- Piedmont Pharmaceuticals LLC, a specialty pharmaceutical company focused on parasitology and drug delivery systems for human and companion animal use, has secured $8.5 million in Series B financing from CM Capital Investments of Brisbane, Australia, and other accredited investors.

This funding will help advance development of Piedmont Pharmaceuticals' pipeline, particularly the U.S. Phase III clinical trials of its unique patented, insecticide-free head lice treatment. Through licensees abroad, this pediculicide rinse is already approved and is the market leader in the United Kingdom and Ireland (under the name Full Marks Solution(R)) and gaining market share in Canada (as RESULTZ(R)). While no timetable has been set, Piedmont Pharmaceuticals anticipates expanding distribution of the product through licensees in the European, Asian and Australasian markets.

"We are very pleased to be working with an investment company of CM Capital's geographical scope and expertise," said Roland Johnson, CEO and Chairman of the Board for Piedmont Pharmaceuticals. "We believe this investment, the first major institutional backing for Piedmont Pharmaceuticals, sends a strong signal about our company's progress and potential. As we move our pediculicide compound through Phase III trials and continue developing the rest of our portfolio, we welcome the guidance and global connections that CM Capital can offer."

"CM Capital invests in companies that can achieve market leadership positions in their respective market sectors," said Andy Jane, partner at CM Capital Investments. "With its talented and proven team of industry veterans, Piedmont Pharmaceuticals has an excellent opportunity to succeed in both the human and animal health markets in the U.S. and beyond."

Members of Piedmont Pharmaceuticals' team have worked together in the health care industry for more than 20 years, bringing more than 11 products to market
'/>"/>

SOURCE Piedmont Pharmaceuticals LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... York (PRWEB) September 22, 2014 ... Boston Scientific Corp. continue to move forward in ... District Court, Southern District of West Virginia, Bernstein ... new Docket Control Order was issued by the ... of matters pertaining to the upcoming trial for ...
(Date:9/22/2014)... percent of patients undergoing breast cancer surgery require additional ... cancerous tissue in the initial operation. However, researchers at ... tool they developed that will help surgeons better distinguish ... chances for repeat operations. , The ... 2014 in the Proceedings of the National Academy ...
(Date:9/22/2014)... PITTSBURGH, PA (PRWEB) September 22, 2014 ... caring for patients to the problem of side-sleeping. "My ... my side, so I designed a solution to this ... fall asleep comfortably than to have your arm 'fall ... sleep on his or her side more comfortably. It ...
(Date:9/22/2014)... The R&D of cancer vaccines has seen ... important data received from clinical research studies have confirmed ... challenge to the development of such vaccines is the ... how a human’s immune system works. The administration of ... owing to known factors with genetics possibly playing a ...
(Date:9/22/2014)... Barbara Bronson Gray ... -- It,s something every pregnant woman wonders: What can I ... suggests that taking iron supplements as prescribed may play a ... autism spectrum disorder (ASD). The researchers found that mothers ... taken iron supplements before and during pregnancy than those whose ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Boston Scientific Litigation, Bernstein Liebhard LLP Reports 4Health News:The fine line between breast cancer and normal tissues 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3
... interested in pursuing careers in health, science or mathematics-related ... Carolina Student Loan Program for Health, Science and Mathematics ... information site, CFNC.org. , ... for Health, Science and Mathematics (HSM) was established in ...
... Robert W. Woodruff Foundation has pledged $3 million toward ... of Dentistry building. , "This is great news for ... helps demonstrate to other foundations and corporations, and to ... contingent upon groundbreaking for the new building during the ...
... MILWAUKEE, Dec. 15 Aurora Health Care announced ... largest radiology,practices in southeastern Wisconsin, have chosen to join Aurora ... 33 Great Lakes radiologists practice chiefly at Aurora hospitals and,clinics. ... physicians who every day contribute to the quality,of the care ...
... one small chocolate truffle can induce cravings for more ... high-end status products, according to a new study in ... a study that examined goals and behavior in consumers, ... (University of Florida) found that study participants who consumed ...
... transparency , , PITTSBURGH, ... its members with online physician quality information in an effort ... , , "Today, more people ... obtain the best care at the best price," said Dr. ...
... the efficacy of The Pink Patch for weight control ... kg) in 4 weeks. The Pink Patch is a ... weight loss goals. Dr. Hudson stated in her ... any dietary or activity changes, The Pink Patch, can ...
Cached Medicine News:Health News:North Carolina Student Loan Program for Health, Science and Mathematics Application Will Be Available December 20, 2008 2Health News:Woodruff Foundation pledges $3 million toward MCG dental building 2Health News:Great Lakes Radiologists to Join Aurora Medical Group 2Health News:Slippery slope: 1 tiny truffle can trigger desire for more treats 2Health News:Highmark Blue Cross Blue Shield Provides Online Physician Quality Information to Members 2Health News:Double Blind Study Proves The Pink Patch Works for Weight Loss 2Health News:Double Blind Study Proves The Pink Patch Works for Weight Loss 3
(Date:9/22/2014)... , Sept. 22, 2014  AbbVie (NYSE: ... several clinical studies evaluating potential new medicines in ... the upcoming 2014 European Society of Medical Oncology ... Madrid, Spain . Data being presented include ... safety and efficacy of veliparib (ABT-888), a poly ...
(Date:9/22/2014)... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today ... overview and update at the NewsMakers in the Biotech ... a.m. Eastern Time (8:30 a.m. Pacific Time), at the ... . A live audio webcast of ... section of Arena,s website at www.arenapharm.com . A ...
(Date:9/22/2014)... , September 22, 2014 ... "Cell Line Development Market by Product (Equipment, Media and ... Tissue Engineering & Regenerative medicine, Toxicity Testing, Research, ... 2019", published by MarketsandMarkets, analyzes and studies the ... Browse 114 market data tables and ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
... Dec. 7 Access Pharmaceuticals, Inc.,(OTC Bulletin ... demonstrated the,ability, using the company,s proprietary Cobalamin(TM) ... animal model of diabetes, through,its oral insulin ... based upon the body,s natural absorption of ...
... DENVER, Dec. 6 Some 5,000 COPD patients ... Antitrypsin Deficiency (Alpha-1) in,a study marking a major ... Association for Respiratory Care (AARC)., The principal ... the,Division of Pulmonary Medicine, National Jewish Medical and ...
Cached Medicine Technology:Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin 2Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin 3Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 2Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 3